JP Morgan Maintains Neutral on Cleveland-Cliffs, Raises Price Target to $13
JP Morgan analyst Bennett Moore maintains Cleveland-Cliffs (NYSE:CLF) with a Neutral and raises the price target from $11 to $13.
Stocks · News reference
CNBC Halftime Report Final Trades: Charles Schwab, Cleveland-Cliffs, UnitedHealth Group, Incyte
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of steel and industrial metal-related companies are trading higher. July's Factor Order data could signal growing demand, and the Beige Book noted increased manufacturing activity across most districts.
CORRECTION: United Steelworkers Announces Negotiations To Continue With U.S. Steel, Cleveland Cliffs Steel
https://usw.org/press-release/bargaining-will-continue-past-expiration-with-u-s-steel-and-cleveland-cliffs/
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Incyte Announces Agreement With CMS To Offer Jakafi And Jakafi XR To State Medicaid Programs At Prices Aligned With Other Industrialized Nations; Says It Does Not Expect Impact To 2026 Guidance
8-K filing — INCYTE CORP (INCY)
Filed: 2026-08-31 AccNo: 0000879169-26-000058 Size: 135 KB Item 8.01: Other Events